A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Latest Information Update: 15 Feb 2024
At a glance
- Drugs Ivosidenib (Primary)
- Indications Astrocytoma; Cholangiocarcinoma; Chondrosarcoma; Glioma; Oligodendroglioma; Solid tumours
- Focus Adverse reactions
- Sponsors Agios Pharmaceuticals
- 09 Feb 2024 Status changed from active, no longer recruiting to completed.
- 01 Dec 2023 Planned End Date changed from 30 Nov 2023 to 30 Dec 2023.
- 01 Dec 2023 Planned primary completion date changed from 30 Nov 2023 to 30 Dec 2023.